On February 10, 2026, Galux announced the successful completion of a $29 million Series B financing (approximately 42 billion KRW). Following this round, the company’s total cumulative funding reached $47 million (around 68 billion KRW).

The Series B round brought together a number of long-term and new institutional investors. Existing investors including InterVest, DAYLI Partners, and PATHWAY Investment participated in the round, while new investors comprised Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities, and Mirae Asset Securities.

Galux previously completed an $18 million Series A financing in 2022 (approximately 21 billion KRW), which supported the upgrade of its AI platform and the enhancement of its R&D capabilities. Since then, the company has achieved multiple key R&D and commercial milestones. The successful completion of the Series B round further validates its execution capabilities and growth momentum.

Dr. Sang-gyun Kim, Managing Director at InterVest, stated: “Since our initial seed investment, Galux has consistently demonstrated strong technological expertise and rigorous execution. The company has successfully built a globally competitive de novo protein design AI platform, strengthening our confidence in its technological strength and long-term potential to transform the drug discovery industry.”

Galux has developed GaluxDesign, an AI-driven protein design platform focused on de novo antibody design — one of the most technically challenging directions in the field. GaluxDesign has successfully generated high-affinity antibodies against multiple therapeutic targets, and the AI-designed antibody structures have shown high consistency with those resolved via cryo-electron microscopy (cryo-EM), fully validating the platform’s accuracy and generalizability.

By deeply integrating cutting-edge AI technologies with efficient experimental feedback from its in-house wet lab, the company is rapidly improving the precision and reliability of its platform. Building on this foundation, the platform’s applications are expanding into more challenging target classes, including G protein-coupled receptors (GPCRs) and ion channels.

Leveraging its technological advantages, Galux continues to expand strategic collaborations. The company has established co-development partnerships with major Korean pharmaceutical firms including Celltrion and LG Chem, and recently announced a collaboration with Boehringer Ingelheim — a significant milestone in its global expansion.

Proceeds from the current financing will be used to further upgrade the company’s AI platform, expand R&D infrastructure, and accelerate preclinical validation of its in-house pipeline. Through these efforts, Galux aims to unlock novel therapeutic opportunities and push the boundaries of drug discovery toward target classes traditionally difficult to address with conventional methods.

Cha-ok Seok, Chief Executive Officer of Galux, commented: “Rapidly evolving AI technologies are driving a paradigm shift in drug discovery — from empirical discovery to rational drug design. This funding will accelerate the development of our next-generation AI technologies, which will overcome limitations in binder design by integrating functional activity and developability engineering to create more stable and therapeutically viable molecules.”